{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-164595","form_type":"8-K/A","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2024-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.257589+00:00","generated_at":"2026-06-01T03:38:10.048892+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"medium","headline":"Nuvation Bio files 8-K/A with AnHeart financials and updated taletrectinib clinical data","bullets":["Acquired AnHeart in Apr 2024; audited AnHeart FY2023 and FY2022 financials included.","Taletrectinib TRUST-I: 90.6% cORR in TKI-naive ROS1+ NSCLC; median PFS not reached at 23.5 mo f/u.","Intracranial cORR 87.5% (TKI-naive) and 73.3% (TKI-pretreated) in TRUST-I; low neuro TEAEs.","NDA accepted in China with priority review for taletrectinib; Breakthrough Therapy in US and China.","Innovent out-license: $55M received; up to $29M regulatory + $105M commercial milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-164595","json":"https://secwatch.observer/filing/0001193125-24-164595.json","markdown":"https://secwatch.observer/filing/0001193125-24-164595.md","text":"https://secwatch.observer/filing/0001193125-24-164595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/0001193125-24-164595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312524164595/d837366d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:38:10.048892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}